Bordeaux Wealth Advisors LLC Acquires 823 Shares of Johnson & Johnson (NYSE:JNJ)

view original post

Bordeaux Wealth Advisors LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 17.5% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,525 shares of the company’s stock after buying an additional 823 shares during the period. Bordeaux Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $979,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of JNJ. Norges Bank acquired a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $4,172,929,000. BlackRock Inc. raised its position in shares of Johnson & Johnson by 2.6% during the fourth quarter. BlackRock Inc. now owns 200,021,352 shares of the company’s stock worth $34,217,654,000 after purchasing an additional 4,982,885 shares during the period. GQG Partners LLC raised its position in Johnson & Johnson by 1,109.4% in the 4th quarter. GQG Partners LLC now owns 3,954,383 shares of the company’s stock valued at $676,375,000 after buying an additional 3,627,424 shares during the last quarter. State Street Corp raised its position in Johnson & Johnson by 1.8% in the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock valued at $24,750,004,000 after buying an additional 2,492,359 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in Johnson & Johnson by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 44,405,610 shares of the company’s stock valued at $7,576,867,000 after buying an additional 1,084,834 shares during the last quarter. 68.78% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on JNJ shares. UBS Group lowered their price target on Johnson & Johnson from $185.00 to $180.00 in a research report on Thursday, July 21st. Citigroup lowered their price target on Johnson & Johnson from $205.00 to $201.00 in a research report on Wednesday, July 20th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. The Goldman Sachs Group raised their target price on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a research report on Tuesday, April 12th. Finally, Morgan Stanley raised their target price on Johnson & Johnson from $173.00 to $174.00 and gave the company an “equal weight” rating in a research report on Friday, July 8th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Stock Up 0.2 %

JNJ stock opened at $174.52 on Monday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 1.14 and a current ratio of 1.39. The company has a market capitalization of $459.23 billion, a price-to-earnings ratio of 25.40, a PEG ratio of 3.28 and a beta of 0.63. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The stock has a fifty day moving average of $175.95 and a 200-day moving average of $174.46.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. Johnson & Johnson had a return on equity of 36.56% and a net margin of 19.21%. The firm’s quarterly revenue was up 3.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.48 EPS. As a group, equities research analysts predict that Johnson & Johnson will post 10.05 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 6th. Shareholders of record on Tuesday, August 23rd will be paid a $1.13 dividend. The ex-dividend date of this dividend is Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.59%. Johnson & Johnson’s dividend payout ratio is currently 65.79%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction dated Friday, June 10th. The stock was sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now owns 71,311 shares in the company, valued at approximately $12,336,803. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CAO Robert J. Decker sold 8,462 shares of the firm’s stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total value of $1,523,160.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The disclosure for this sale can be found here. 0.35% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.

Related Posts